Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours

Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belusa R

Authors: Knigge U, Kjellman M, Grønbæk H, Thiis-Evensen E, Schalin-Jäntti C,

Keywords: prediction, progression, machine learning, SI-NET, serum protein,

#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease

Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Sponheim J,

Keywords: Neuroendocrine tumor, Treatment, Radiology, Time to progression,

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours

Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sorbye H

Authors: Sorbye H, Meyer L, Mordal K, Myhre S, Thiis-Evensen E,

Keywords: Quality of life, small-intestinal neuroendocrine tumors, patient reported symptoms, coping, somatostatin analogue,

#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dam G, Grønbæk H, Sørbye H, Thiis-Evensen E, Paulsson B,

Keywords: gep-net, ct, cga, correlation,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!


The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.